The evolution of drug discovery in systemic lupus erythematosus

Nature Reviews Rheumatology

Volumn 11, Issue 10, 2015, Pages 616-620

  Wallace, Daniel J ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BELIMUMAB; CHLORAMBUCIL; CHLORMETHINE; CHLOROQUINE; CHLOROQUINE PLUS HYDROXYCHLOROQUINE SULFATE PLUS MEPACRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDROXYCHLOROQUINE; LEFLUNOMIDE; MEPACRINE; METHOTREXATE; MYCOPHENOLIC ACID; PRASTERONE; PREDNISONE; TACROLIMUS; TORALIZUMAB;

CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; METHODOLOGY; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; REVIEW; RHEUMATIC DISEASE; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; DRUG DEVELOPMENT; LUPUS ERYTHEMATOSUS, SYSTEMIC; TRENDS;

CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84943364077     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2015.86     Document Type: Review

References (41)

1. Lim S. S., et al. The incidence and prevalence of systemic lupus erythematosus: the Georgia Lupus Registry. Arthritis Rheum. 66, 357-368 (2014
2. Tye M. J., White H., Appel B., & Ansell H. B. Lupus erythematosus treated with a combination of quinacrine, hydroxychloroquine and chloroquine. N. Engl. J. Med. 260, 63-66 (1959
3. Mc Cune W. J., Marder W. E., & Riskaila M. in Dubois' Lupus Erythematosus 7th edn (eds Wallace D. J., & Hahn B. H.) 1198-1224 (Wolters Kluwer, 2007
4. Balow J. E., et al. NIH conference. Lupus nephritis. Ann. Intern. Med. 106, 79-94 (1987
5. Steinberg A. D., & Steinberg S. C. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum. 34, 945-950 (1991
6. Wallace D. J. A critique of the NIH lupus nephritis survey. Arthritis Rheum. 35, 605-607 (1992
7. Lewis E. J., Hunsicker L. G., Lan S. P., Rohde R. D., & Lachin J. M. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N. Engl. J. Med. 326, 1373-1379 (1992
8. Ginzler E. M., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353, 2219-2228 (2005
9. No authors listed] A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N. Engl. J. Med. 324, 150-154 (1991
10. Fortin P. R., et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 59, 1796-1804 (2008
11. Mok C. C., et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomized controlled trial and long-term follow up. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis 2014 206456
12. Remer C. F., Weisman M. H., & Wallace D. J., Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 10, 480-483 (2001
13. Houssiau F. A., et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann. Rheum. Dis. 69, 61-64 (2010
14. Petri M. A., et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 46, 1820-1829 (2002
15. Crosbie D., Black C., McIntyre L., Royle P., & Thomas S. Dehydroepiandrosterone for systemic lupus erythematosus. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD005114. http://dx.doi.org/10.1002/14651858.CD005114.pub2
16. Boumpas D. T., et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48, 719-727 (2003
17. Kalunian K. C., et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD 154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 3251-3258 (2002
18. U.S. Food and Drug Administration. Guidance for industry on systemic lupus erythematosus: developing drugs for treatment. Federal Register 70, 15868 (2005
19. U.S. Food and Drug Administration. Guidance for industry on lupus nephritis caused by systemic lupus erythematosus-developing medical products for treatment; withdrawal of guidance. Federal Register [online], https://federalregister.gov/a/2012-15716 (2012
20. U.S. Food and Drug Administration. Guidance for industry on systemic lupus erythematosus: developing medical products for treatment. U.S. Food and Drug Administration: Guidances (Drugs) [online], http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064981.htm (2010
21. Furie R. A., et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 61, 1143-1151 (2009
22. Urowitz M. B., Gladman D. D., Tozman E. C., & Goldsmith C. H. The Lupus Activity Criteria Count (LACC). J. Rheumatol. 11, 783-787 (1984
23. Strand V., et al. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J. Rheumatol. 26, 490-497 (1999
24. Strand V. in Dubois' Lupus Erythematosus 7th edn (eds Wallace D. J., & Hahn B. H.) 1317-1332 (Wolters Kluwer, 2007
25. Van Vollenhoven R. in Dubois' Lupus Erythematosus and Related Syndromes 8th edn (eds Wallace D. J., & Hahn B. H.) 648-652 (Elsevier, 2013
26. Isenberg D. A., et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus (SLE): results from 2 phase 3, 52-week, multicenter, randomized, double-blind, placebo-controlled trials [abstract L25]. Presented at the American College of Rheumatology/ARHP 2014 Annual Scientific Meeting, Boston, MA, USA
27. Cardiel M
28. Mysler E. F., et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum.65, 2368-2379 (2013
29. Aranow C., et al. A phase 2 multicenter randomized double-blind, placebo-controlled, proof of concept study to evaluate the efficacy and safety of sirukumab in patients with active lupus nephritis [abstract 2835]. Arthritis Rheum. 66 (Suppl.), S1239 (2014
30. Kalunian K. C., et al. A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2014-206090
31. Isenberg D., et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate to severe systemic lupus erythematosus (SLE): 52 week data (APRIL-SLE randomized trial. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis 2013 205067
32. Merrill J. T., et al. The efficacy and safety of abatacept in patients with non life threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62, 3077-3087 (2010
33. Urowitz M., Isenberg D., & Wallace D. J. Prelude-Edratide phase-II study outcome-from predefined analyses to more recent assessment approaches. Ann. Rheum. Dis. 70 (Suppl. 3), 315 (2011
34. Zimmer R., Scherbarth H. R., Rillo O. L., Gomez-Reino J. J., & Muller S. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann. Rheum. Dis. 72, 1830-1835 (2013
35. Illei G. G., et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 62, 542-552 (2010
36. Furie R. A., et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate to severe systemic lupus erythematosus, the PEARL SC study. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis 2013 205144
37. Khamastha M., et al. Safety and efficacy of sifalimumab, an anti interferon-α monoclonal antibody in a phase 2b study of moderate to severe SLE [abstract L4]. Arthritis Rheum. 66 (Suppl. 1), S312 (2014
38. Wallace D. J., et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomized, double-blind, placebo-controlled, multicenter study. Ann. Rheum. Dis. 73, 183-190 (2014
39. Aringer M., et al. Adverse events and efficacy of TNF-α blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 48, 1451-1454 (2009
40. Merrill J. T., et al. Efficacy and safety of rituximab in moderately to severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 1215-1227 (2010
41. Cortés-Hernández J., Egri N., Vilardell-Tarrés M., & Ordi-Ros J. Etanercept in refractory lupus arthritis: an observational study. Semin. Arthritis Rheum. http://dx.doi.org/10.1016/j.semarthrit.2015.01.006